美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Range Cancer Therapeutics ETF

9.02

0.0000

成交量：- -

成交額：- -

市值：704.29萬

市盈率：23.74

高：9.02

開：9.02

低：9.02

收：9.02

52周最高：9.02

52周最低：9.02

股本：78.08萬

流通股本：78.08萬

量比：- -

換手率：- -

股息：0.00

股息率：0.01%

每股收益(TTM):0.3800

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

REGENXBIO股價下跌24%，此前美國食品藥品監督管理局暫停了該公司針對亨特綜合徵的基因療法的臨床試驗。

【券商聚焦】中信建投：腫瘤mRNA疫苗開創腫瘤治療新範式，國內企業加速追趕

中信建投：腫瘤mRNA疫苗開創腫瘤治療新範式國內企業加速追趕

FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格

环球市场播报

中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局

【券商聚焦】中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局

中信建投：解鎖不可成藥靶點 RAS藥物打開腫瘤治療新格局

中大與南沙區政府、廣州市第一人民醫院共建大灣區首個國際研究推進AI脊柱側彎篩查及膝骨關節炎幹細胞療法

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/CNCR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1787601600000,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"未開盤","change":0,"latestTime":"08-24 16:00:00 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","floatShares":780814,"roa":"--","roe":"--","lyrEps":0,"shares":780814,"dividePrice":0.001,"high":9.02,"amplitude":0,"preClose":9.02,"low":9.02,"week52Low":9.02,"pbRate":"--","week52High":9.02,"institutionHeld":0,"latestPrice":9.02,"eps":0.38,"divideRate":0.000111,"volume":0,"delay":0,"ttmEps":0.38,"open":9.02,"prevYearClose":9.02,"prevWeekClose":9.02,"prevMonthClose":9.02,"prevQuarterClose":9.02,"fiveDayClose":9.02,"twentyDayClose":9.02,"sixtyDayClose":9.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-28","symbol":"CNCR","reason":null,"defaultRemindTime":1748439000000,"announcedDate":"2025-05-27","type":"delisting","dateTimestamp":1748404800000},{"market":"US","date":"2021-12-29","symbol":"CNCR","amount":1.8533352,"defaultRemindTime":1640788200000,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000},{"market":"US","date":"2020-12-30","symbol":"CNCR","amount":0.2881193,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-01-04","payableDate":"2020-12-31","currency":"USD","type":"dividend","dateTimestamp":1609304400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNCR\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-30","recordDate":"2020-12-31","paymentDate":"2021-01-04","value":0.2881193,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":1.8533352,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNCR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNCR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661271420","title":"REGENXBIO股價下跌24%，此前美國食品藥品監督管理局暫停了該公司針對亨特綜合徵的基因療法的臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271420?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 21:32","pubTimestamp":1787578348,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","PSYK","CNCR","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244441","title":"【券商聚焦】中信建投：腫瘤mRNA疫苗開創腫瘤治療新範式，國內企業加速追趕","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244441","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661244441?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 09:19","pubTimestamp":1787534349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，随着Moderna个性化肿瘤mRNA疫苗临床III期取得积极结果，mRNA肿瘤疫苗正朝着商业化阶段迈进，市场空间有望逐步打开。mRNA肿瘤疫苗与ICIs联用有望开创肿瘤治疗的新范式。分类来看，个性化肿瘤疫苗具有潜在更优的治疗效果，虽然生产成本较高，但也有更大的定价空间，而通用型疫苗凭规模化生产和较低成本，有望覆盖更广泛的患者群体。AI有望赋能多个环节，加速mRNA肿瘤疫苗的迭代升级。目前国内肿瘤mRNA疫苗研发正加速追赶，未来有望实现差异化突破，相关企业及产业链公司有望受益。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989097","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0737861772.HKD","CANC","MRNY","KCE","MRNX","601066","06078","CNCR","LU0329678170.USD","BK1583","BK1209","BK0276","LU2488822045.USD","LU0329678337.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661991241","title":"中信建投：腫瘤mRNA疫苗開創腫瘤治療新範式 國內企業加速追趕","url":"https://stock-news.laohu8.com/highlight/detail?id=2661991241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661991241?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 08:26","pubTimestamp":1787531164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","MRNX","CNCR","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656875551","title":"FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656875551?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。　　2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["WDNA","CNCR","LABU","BK4585","SYNB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346962","title":"中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346962?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 07:56","pubTimestamp":1785715006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652473201","title":"【券商聚焦】中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652473201","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652473201?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 08:56","pubTimestamp":1784249779,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，RAS是人类肿瘤中最重要的致癌驱动基因家族之一，主要包括KRAS、NRAS和HRAS，其中KRAS占据核心地位。 RAS靶向治疗已从G12C单点突破，进入G12D、Pan-KRAS和Pan-RAS(ON)多路线推进阶段，管线布局和临床验证正在逐步丰富。2026年ASCO大会上，RMC-6236在2L转移性胰腺癌III期研究中取得积极结果，中位OS较化疗接近翻倍，进一步强化了市场对RAS靶向治疗临床价值的期待。国内企业也在G12D、Pan-RAS、Pan-KRAS等多方向积极跟进。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986095","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601066","LU0329678337.USD","LU0737861772.HKD","LU0329678170.USD","BK1583","KCE","BK1209","CANC","LU2488822045.USD","BK0276","06078","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652781264","title":"中信建投：解鎖不可成藥靶點 RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652781264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652781264?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 08:00","pubTimestamp":1784246446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651637415","title":"中大與南沙區政府、廣州市第一人民醫院共建大灣區首個國際研究 推進AI脊柱側彎篩查及膝骨關節炎幹細胞療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2651637415","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651637415?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 13:23","pubTimestamp":1784179380,"startTime":"0","endTime":"0","summary":"香港中文大学（中大）与广州市南沙区人民政府及广州市第一人民医院今日签署三方合作协议，共同建设‘香港中文大学大湾区临床研究中心’，推动粤港澳大湾区跨境临床研究合作及医疗创新发展，提升大湾区临床研究能力及医疗服务质素，加快创新药物和医疗技术的研发与应用，惠及更多病人。　　合作协议由广州市南沙区人民政府副区长马洁红女士、中大医学院院长赵伟仁教授及广州市第一人民医院党委书记付涌水教授签署。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2026-07-16/doc-inihyqhe4432326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159983","AIPO","CNCR","QTOC","VTHR","WDNA","SYNB","ARTY","CHAT","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}